155 related articles for article (PubMed ID: 11060749)
41. In vitro and in vivo antitumour effects of novel, orally active bile acid-conjugated platinum complexes on rat hepatoma.
Barbara C; Orlandi P; Bocci G; Fioravanti A; Di Paolo A; Natale G; Del Tacca M; Danesi R
Eur J Pharmacol; 2006 Nov; 549(1-3):27-34. PubMed ID: 16978599
[TBL] [Abstract][Full Text] [Related]
42. Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids.
Solovyev ND; Fedoros EI; Drobyshev EJ; Ivanenko NB; Pigarev SE; Tyndyk ML; Anisimov VN; Vilpan YA; Panchenko AV
J Trace Elem Med Biol; 2017 Sep; 43():72-79. PubMed ID: 27986470
[TBL] [Abstract][Full Text] [Related]
43. Platinum anticancer drugs. From serendipity to rational design.
Monneret C
Ann Pharm Fr; 2011 Nov; 69(6):286-95. PubMed ID: 22115131
[TBL] [Abstract][Full Text] [Related]
44. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.
Sternberg CN; Petrylak DP; Sartor O; Witjes JA; Demkow T; Ferrero JM; Eymard JC; Falcon S; Calabrò F; James N; Bodrogi I; Harper P; Wirth M; Berry W; Petrone ME; McKearn TJ; Noursalehi M; George M; Rozencweig M
J Clin Oncol; 2009 Nov; 27(32):5431-8. PubMed ID: 19805692
[TBL] [Abstract][Full Text] [Related]
45. In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines.
Fiebiger W; Olszewski U; Ulsperger E; Geissler K; Hamilton G
Clin Transl Oncol; 2011 Jan; 13(1):43-9. PubMed ID: 21239354
[TBL] [Abstract][Full Text] [Related]
46. A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.
Gallerani E; Cathomas R; Sessa C; Digena T; Bartosek AA; Dal Zotto L; von Moos R
Onkologie; 2013; 36(1-2):40-5. PubMed ID: 23429330
[TBL] [Abstract][Full Text] [Related]
47. [Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II)].
Ota K; Wakui A; Majima H; Niitani H; Inuyama Y; Ogawa M; Ariyoshi Y; Yoshida O; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1992 Jun; 19(6):855-61. PubMed ID: 1605663
[TBL] [Abstract][Full Text] [Related]
48. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
49. Promising new developments in cancer chemotherapy.
Ferrante K; Winograd B; Canetta R
Cancer Chemother Pharmacol; 1999; 43 Suppl():S61-8. PubMed ID: 10357561
[TBL] [Abstract][Full Text] [Related]
50. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
[TBL] [Abstract][Full Text] [Related]
51. Phase I study of oral JM216 given twice daily.
Beale P; Raynaud F; Hanwell J; Berry C; Moore S; Odell D; Judson I
Cancer Chemother Pharmacol; 1998; 42(2):142-8. PubMed ID: 9654114
[TBL] [Abstract][Full Text] [Related]
52. Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies.
Zander T; Xue J; Markson G; Dahm F; Renner C
Anticancer Res; 2022 Apr; 42(4):1821-1832. PubMed ID: 35347000
[TBL] [Abstract][Full Text] [Related]
53. A better platinum-based anticancer drug yet to come?
Olszewski U; Hamilton G
Anticancer Agents Med Chem; 2010 May; 10(4):293-301. PubMed ID: 20187870
[TBL] [Abstract][Full Text] [Related]
54. A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Gallerani E; Bauer J; Hess D; Boehm S; Droege C; Jeckelmann S; Miani M; Herrmann R; Marsoni S; Sperka S; Sessa C
Acta Oncol; 2011 Oct; 50(7):1105-10. PubMed ID: 21184645
[TBL] [Abstract][Full Text] [Related]
55. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
56. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
Curt GA; Grygiel JJ; Corden BJ; Ozols RF; Weiss RB; Tell DT; Myers CE; Collins JM
Cancer Res; 1983 Sep; 43(9):4470-3. PubMed ID: 6347373
[TBL] [Abstract][Full Text] [Related]
57. Results of NCI-sponsored phase I trials with carboplatin.
Foster BJ; Clagett-Carr K; Leyland-Jones B; Hoth D
Cancer Treat Rev; 1985 Sep; 12 Suppl A():43-9. PubMed ID: 3910221
[TBL] [Abstract][Full Text] [Related]
58. Modulation of signaling enhances the efficacy of the combination of satraplatin and erlotinib.
Avan A; Adema AD; Hoebe EK; Huijts CM; Avan A; Veal GJ; Ruijtenbeek R; Wosikowski K; Peters GJ
Curr Drug Targets; 2014; 15(14):1312-21. PubMed ID: 25382189
[TBL] [Abstract][Full Text] [Related]
59. Oxaliplatin: pharmacokinetics and chronopharmacological aspects.
Lévi F; Metzger G; Massari C; Milano G
Clin Pharmacokinet; 2000 Jan; 38(1):1-21. PubMed ID: 10668856
[TBL] [Abstract][Full Text] [Related]
60. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]